... to treatment. Methods: We evaluated the IRF4 expression kinetics during tyrosine kinase inhibitor (TKI) treatment in a cohort of 116 chronic myeloid leukemia (CML) patients to elucidate its role in the disease course. Results: A relationship between the IRF4 expression and the disease burden was observed...

... Background: Philadelphia chromosome-positive (Ph+) advanced leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in myeloid blast phase (MBP), have poor outcomes. Venetoclax has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKI) in preclinical studies. However...

...Bachar Samra; Hagop M. Kantarjian; Koji Sasaki; Ahmad S. Alotaibi; Marina Konopleva; Susan O’Brien; Alessandra Ferrajoli; Rebecca Garris; Cesar A. Nunez; Tapan M. Kadia; Nicholas J. Short; Elias Jabbour Background: The addition of tyrosine kinase inhibitors (TKIs) to chemotherapy has dramatically...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Tyrosine kinase inhibitors Age Comorbidities Feasibility of discontinuation Quality...

... conditions associated with CML at different times during the course of the disease. All 8 patients were treated with tyrosine kinase inhibitors at some point during the course of their illness. The literature regarding the uncommon association of these apparently unrelated disorders is reviewed as well...

...-ABL Philadelphia chromosome-positive acute lymphoblastic leukaemia. We detected three BCR-ABL1 clones determined by the presence of the E255V, D276G and F317L mutations. We point out the usefulness of searching for mutated populations that survive tyrosine-kinase inhibitor therapy and the role...

...Aline Fernanda Ferreira; Gislane L.V. de Oliveira; Raquel Tognon; Maria Dulce S. Collassanti; Maria Aparecida Zanichelli; Nelson Hamerschlak; Ana Maria de Souza; Dimas Tadeu Covas; Simone Kashima; Fabiola Attie de Castro Background/Aims: We investigated the effects of tyrosine kinase inhibitors...

... JAK2 mutation Tyrosine kinase inhibitors Chronic myeloproliferative neoplasms (CMPNs) are rare diseases of hematopoietic stem cells that are characterized by clonal expansion of one or more myeloid precursor cells. The four most frequent diseases of this group are chronic myelogenous leukemia...

...Anthony Oyekunle; Evgeny Klyuchnikov; Sunday Ocheni; Nicolaus Kröger; Axel R. Zander; Michele Baccarani; Ulrike Bacher Following the introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of chronic myeloid leukemia (CML) patients, the allogeneic hematopoietic stem cell...